| 000 | 01911 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250514234330.0 | ||
| 264 | 0 | _c20060929 | |
| 008 | 200609s 0 0 eng d | ||
| 022 | _a0340-5354 | ||
| 024 | 7 |
_a10.1007/s00415-005-0934-5 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aColes, Alasdair J | |
| 245 | 0 | 0 |
_aThe window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. _h[electronic resource] |
| 260 |
_bJournal of neurology _cJan 2006 |
||
| 300 |
_a98-108 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Evaluation Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAlemtuzumab |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntibodies, Neoplasm _xadministration & dosage |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAutoimmunity _xdrug effects |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 | _aDisability Evaluation |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInfant |
| 650 | 0 | 4 |
_aMagnetic Resonance Imaging _xmethods |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMultiple Sclerosis _xtherapy |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSecondary Prevention |
| 650 | 0 | 4 | _aTime Factors |
| 700 | 1 | _aCox, Amanda | |
| 700 | 1 | _aLe Page, Emmanuelle | |
| 700 | 1 | _aJones, Joanne | |
| 700 | 1 | _aTrip, S Anand | |
| 700 | 1 | _aDeans, Jackie | |
| 700 | 1 | _aSeaman, Shaun | |
| 700 | 1 | _aMiller, David H | |
| 700 | 1 | _aHale, Geoff | |
| 700 | 1 | _aWaldmann, Herman | |
| 700 | 1 | _aCompston, D Alastair | |
| 773 | 0 |
_tJournal of neurology _gvol. 253 _gno. 1 _gp. 98-108 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00415-005-0934-5 _zAvailable from publisher's website |
| 999 |
_c15697850 _d15697850 |
||